文献速递甲状腺疾病

散发性与遗传性甲状腺髓样癌的分期依赖性生存与结局相似

Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该回顾性研究纳入1974年至2019年在德国三级转诊中心手术的673例甲状腺髓样癌患者,比较散发性(sMTC)与遗传性(hMTC)的长期疾病特异性生存(DSS)和结局。两组诊断年龄和肿瘤分期显著不同,总体DSS有差异,但分期依赖性DSS和结局相似;多因素分析中sMTC与hMTC的DSS无差异,而诊断年龄、男性和III/IV期与更差DSS显著相关。结论提示两者肿瘤行为相似。

要点

  • sMTC与hMTC的分期依赖性DSS和结局相似,提示肿瘤行为相近。
  • 多因素分析中sMTC与hMTC的DSS无显著差异(HR=1.56;95%CI 0.94-2.57)。
  • 诊断年龄、男性和III/IV期是DSS更差的显著相关因素。

核心结论

  • sMTC与hMTC患者发病年龄不同,但诊断后分期依赖性DSS和结局相似,提示肿瘤行为相似。

研究设计与样本

  • 回顾性分析,德国三级转诊中心,1974年1月至2019年7月手术的673例甲状腺髓样癌患者(sMTC n=477,hMTC n=196)。

主要发现

  • sMTC手术中位年龄49岁(n=477,44%男性),hMTC为29岁(n=196,43%男性;P<0.0001)。
  • sMTC平均随访9.2±8.0年,hMTC为14.6±10.3年。
  • 两组总体DSS不同(log rank,P=0.0183),但分期依赖性DSS相似(log rank,P=0.1242-0.8981)。
  • 多因素分析中sMTC与hMTC的DSS无差异(HR=1.56;95%CI 0.94-2.57)。
  • 更差DSS与诊断年龄(HR=1.04;95%CI 1.02-1.05)、男性(HR=0.49;95%CI 0.32-0.76)、III期(HR=20.00;95%CI 2.74-145.91)和IV期(HR=97.47;95%CI 13.07-726.67)显著相关。

关键数值与推荐

  • 两组结局(治愈、微小残留病、结构可检测疾病、死亡)显著不同(P<0.0001),但分期依赖性结局相似(P=0.9449-0.0511),仅III期例外(P=0.0489)。

临床怎么用

  • 临床中应依据诊断时分期评估甲状腺髓样癌预后,而非仅区分散发性或遗传性。
  • 对诊断年龄较大、男性、III/IV期患者应加强随访和干预。

局限性

  • 回顾性单中心设计可能引入选择偏倚。
  • 两组随访时间不等,hMTC随访更长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Long-term data are scarce on large cohorts with sporadic (sMTC) and hereditary medullary thyroid carcinoma (hMTC). OBJECTIVES: To compare long-term disease-specific survival (DSS) and outcomes between sMTC and hMTC groups. DESIGN: Retrospective analysis. SETTING: German tertiary referral center. PATIENTS: A total of 673 patients with MTC that underwent surgery from January 1974 to July 2019. INTERVENTION: None (observational study). MAIN OUTCOME MEASURE: Differences between sMTC and hMTC in long-term, stage-dependent survival and outcomes. RESULTS: Surgery was performed at median ages of 49 years for sMTC (n = 477, 44% male) and 29 years for hMTC (n = 196, 43% male; P < 0.0001). The mean follow-up times were 9.2 ± 8.0 (sMTC) and 14.6 ± 10.3 years (hMTC). Age and tumor stage at diagnosis were significantly different between the 2 groups (P < 0.0001). The sMTC and hMTC groups had different overall DSS (log rank, P = 0.0183), but similar stage-dependent DSS (log rank, P = 0.1242-0.8981). In a multivariate analysis, sMTC and hMTC did not differ in DSS (hazard ratio [HR] = 1.56; 95% CI, 0.94-2.57), but in both groups, a worse DSS was significantly associated with age at diagnosis (HR = 1.04; 95% CI, 1.02-1.05), male sex (HR = 0.49; 95% CI, 0.32-0.76), and stages III and IV at diagnosis (HR = 20.00; 95% CI, 2.74-145.91 and HR = 97.47; 95% CI, 13.07-726.67, respectively). The groups had significantly different (P < 0.0001) outcomes (i.e., cured, minimal residual disease, structural detectable disease, and death), but similar stage-dependent outcomes (P = 0.9449-0.0511), except for stage III (P = 0.0489). CONCLUSION: Patients with sMTC and hMTC had different ages of onset, but similar stage-dependent DSS and outcomes after the MTC diagnosis. This finding suggested that tumor behavior was similar in sMTC and hMTC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Raue F, Bruckner T, Frank-Raue K, et al. Similar Stage-dependent Survival and Outcome in Sporadic and Hereditary Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2021. PMID: 33974051. doi:10.1210/clinem/dgab326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。